Maricarmen D Planas-Silva

Summary

Affiliation: Pennsylvania State University
Country: USA

Publications

  1. ncbi Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells
    Robin L Kilker
    Department of Pharmacology, Penn State College of Medicine, Hershey, PA 17033, USA
    J Steroid Biochem Mol Biol 92:63-71. 2004
  2. ncbi Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer
    Maricarmen D Planas-Silva
    Department of Pharmacology, Penn State College of Medicine, Hershey, PA 17033, USA
    Exp Mol Pathol 82:85-90. 2007
  3. ncbi Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells
    Maricarmen D Planas-Silva
    Department of Pharmacology, Penn State College of Medicine, 500 University Drive, MCH078, Hershey, PA 17033, USA
    J Steroid Biochem Mol Biol 104:11-21. 2007
  4. ncbi Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer
    Maricarmen D Planas-Silva
    Department of Pharmacology, Penn State College of Medicine, Hershey, PA 17033, USA
    Biochem Biophys Res Commun 341:73-81. 2006
  5. ncbi Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant
    Maricarmen D Planas-Silva
    Department of Pharmacology, Penn State College of Medicine, Hershey, PA 17033, USA
    J Steroid Biochem Mol Biol 98:193-8. 2006
  6. ncbi Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins
    Maricarmen D Planas-Silva
    Department of Pharmacology, Penn State College of Medicine, 500 University Drive, MCH078, Hershey, PA 17033, USA
    Cancer Chemother Pharmacol 60:535-43. 2007
  7. doi Prevention of age-related spontaneous mammary tumors in outbred rats by late ovariectomy
    Maricarmen D Planas-Silva
    Department of Pharmacology, Penn State College of Medicine, MCH078, 500 University Drive, Hershey, PA 17033, USA
    Cancer Detect Prev 32:65-71. 2008
  8. ncbi Estrogen-dependent regulation of Eg5 in breast cancer cells
    Maricarmen D Planas-Silva
    Department of Pharmacology H078, Pennsylvania State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA
    Anticancer Drugs 18:773-9. 2007
  9. doi Mislocalization of cell-cell adhesion complexes in tamoxifen-resistant breast cancer cells with elevated c-Src tyrosine kinase activity
    Yan Zhao
    Department of Pharmacology, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, USA
    Cancer Lett 275:204-12. 2009
  10. ncbi Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells
    Robin L Kilker
    Department of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania 17033, USA
    Cancer Res 66:11478-84. 2006

Collaborators

Detail Information

Publications13

  1. ncbi Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells
    Robin L Kilker
    Department of Pharmacology, Penn State College of Medicine, Hershey, PA 17033, USA
    J Steroid Biochem Mol Biol 92:63-71. 2004
    ..These studies suggest that estrogen receptor mediates cyclin D1 expression and growth of tamoxifen-resistant tumors...
  2. ncbi Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer
    Maricarmen D Planas-Silva
    Department of Pharmacology, Penn State College of Medicine, Hershey, PA 17033, USA
    Exp Mol Pathol 82:85-90. 2007
    ....
  3. ncbi Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells
    Maricarmen D Planas-Silva
    Department of Pharmacology, Penn State College of Medicine, 500 University Drive, MCH078, Hershey, PA 17033, USA
    J Steroid Biochem Mol Biol 104:11-21. 2007
    ..These studies suggest that antiestrogen therapy and Src family kinase inhibitors may decrease development of metastases in ER-positive breast cancer by blocking estrogen-dependent migration of human breast cancer cells...
  4. ncbi Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer
    Maricarmen D Planas-Silva
    Department of Pharmacology, Penn State College of Medicine, Hershey, PA 17033, USA
    Biochem Biophys Res Commun 341:73-81. 2006
    ..These studies also raise the possibility that fully active forms of c-Src and Fak in breast tumors may be biomarkers to predict tamoxifen resistance and/or risk of recurrence in ER-positive breast cancer...
  5. ncbi Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant
    Maricarmen D Planas-Silva
    Department of Pharmacology, Penn State College of Medicine, Hershey, PA 17033, USA
    J Steroid Biochem Mol Biol 98:193-8. 2006
    ..Moreover, these studies support short-term treatment with estrogen as a second-line hormonal therapy for tamoxifen-resistant breast cancer...
  6. ncbi Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins
    Maricarmen D Planas-Silva
    Department of Pharmacology, Penn State College of Medicine, 500 University Drive, MCH078, Hershey, PA 17033, USA
    Cancer Chemother Pharmacol 60:535-43. 2007
    ..In breast cancer, c-Src has been proposed to mediate the actions of estrogen in cell cycle progression...
  7. doi Prevention of age-related spontaneous mammary tumors in outbred rats by late ovariectomy
    Maricarmen D Planas-Silva
    Department of Pharmacology, Penn State College of Medicine, MCH078, 500 University Drive, Hershey, PA 17033, USA
    Cancer Detect Prev 32:65-71. 2008
    ..However, it is not known whether removal of ovaries late in life, before middle age onset, can still prevent mammary tumor development...
  8. ncbi Estrogen-dependent regulation of Eg5 in breast cancer cells
    Maricarmen D Planas-Silva
    Department of Pharmacology H078, Pennsylvania State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA
    Anticancer Drugs 18:773-9. 2007
    ..30 micromol/l and for monastrol to 112.69 micromol/l. Our results suggest that pharmacological inhibition of Eg5 may be an effective treatment for estrogen receptor-positive breast cancer, even without concomitant hormonal therapy...
  9. doi Mislocalization of cell-cell adhesion complexes in tamoxifen-resistant breast cancer cells with elevated c-Src tyrosine kinase activity
    Yan Zhao
    Department of Pharmacology, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, USA
    Cancer Lett 275:204-12. 2009
    ..These findings suggest that inhibition of c-Src signaling may prevent metastasis of tamoxifen-resistant breast cancer...
  10. ncbi Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells
    Robin L Kilker
    Department of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania 17033, USA
    Cancer Res 66:11478-84. 2006
    ..These results suggest that therapeutic strategies to block cyclin D1 expression or function may inhibit development and growth of tamoxifen-resistant tumors...
  11. pmc Differential gene expression in tamoxifen-resistant breast cancer cells revealed by a new analytical model of RNA-Seq data
    Kathryn J Huber-Keener
    Department of Pharmacology, The Penn State Cancer Institute, The Pennsylvania State University College of Medicine, Milton S Hershey Medical Center, Hershey, Pennsylvania, United States of America
    PLoS ONE 7:e41333. 2012
    ..Alterations of small nucleolar RNA, oxidative phosphorylation, and proliferation processes in Tam-resistant cells present areas for diagnostic and therapeutic tool development for combating resistance to this anti-estrogen agent...
  12. ncbi Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor
    Lois M Witters
    Department of Medicine, H046, Milton S Hershey Medical Center, Hershey, PA 17033, USA
    Oncol Rep 17:465-9. 2007
    ..This study suggests that simultaneously blocking the ErbB family of receptor tyrosine kinases and Bcl-2 family of proteins may be a benefit to breast cancer patients...
  13. doi Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer
    Hongyu Liu
    Department of Oncology and Hematology, University Hospital Charite, Humboldt University of Berlin, Berlin, Germany
    Eur J Pharmacol 591:43-51. 2008
    ..In conclusion, honokiol, either alone or in combination with other therapeutics, could serve as a new, promising approach for breast cancer treatment...